In addition to using the latest finding to guide the care provided to cancer survivors, the Survivorship Program team is dedicated to conducting research to learn more about the long-term and late effects of cancer treatment and to improve the quality of life for survivors.
Our researchers are involved in projects ranging from studying the long-term cardiovascular effects of cancer treatment, to examining the factors that determine emotional adjustment and quality of life.
Eligible survivors are invited to participate in research projects. As part of these efforts, all patients entering survivorship care are asked to complete a series of survivorship questionnaires about their physical, emotional, and medical experiences. This information is collected on an annual basis and helps us guide your survivorship care.
Dr. Scott Baker is Director of the Survivorship Program and the Medical Director of the Pediatric Bone Marrow Transplantation Program at the Fred Hutchinson Cancer Research Center (FHCRC) and the Seattle Cancer Care Alliance (SCCA). Dr. Baker is a Full Member within the Clinical Research Division at FHCRC and is a Member of the Hematology/Oncology Division at Seattle Children's Hospital. Dr. Baker also leads the Cancer Survivorship program for pediatric patients at Seattle Children's. His main focus is on late effects of cancer therapy, in particular in patients that have undergone hematopoietic stem cell transplant.
Dr. Karen Syrjala is Co-Director of the Survivorship Program and Director of Biobehavioral Sciences at the Fred Hutchinson Cancer Research Center (FHCRC). Dr. Syrjala is a Full Member within the Clinical Research Division at FHCRC and Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine. She is a licensed clinical psychologist; and is credited with the establishment of the Psychiatry/Psychology consult service at the Seattle Cancer Care Alliance. She has conducted or participated in over 30 extramurally funded studies with cancer and hematopoietic stem cell transplant survivors.